- Home
- TURN vs LPCN Comparison
TURN vs LPCN Comparison
Compare TURN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- LPCN
- Stock Information
- Founded
- TURN 1981
- LPCN 1997
- Country
- TURN United States
- LPCN United States
- Employees
- TURN N/A
- LPCN N/A
- Industry
- TURN Finance/Investors Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- LPCN Health Care
- Exchange
- TURN Nasdaq
- LPCN Nasdaq
- Market Cap
- TURN 33.4M
- LPCN 36.8M
- IPO Year
- TURN N/A
- LPCN N/A
- Fundamental
- Price
- TURN $3.21
- LPCN $5.46
- Analyst Decision
- TURN
- LPCN Strong Buy
- Analyst Count
- TURN 0
- LPCN 1
- Target Price
- TURN N/A
- LPCN $10.00
- AVG Volume (30 Days)
- TURN 8.1K
- LPCN 23.4K
- Earning Date
- TURN 11-11-2024
- LPCN 11-06-2024
- Dividend Yield
- TURN N/A
- LPCN N/A
- EPS Growth
- TURN N/A
- LPCN N/A
- EPS
- TURN N/A
- LPCN N/A
- Revenue
- TURN $129,297.00
- LPCN $4,800,930.00
- Revenue This Year
- TURN N/A
- LPCN N/A
- Revenue Next Year
- TURN N/A
- LPCN N/A
- P/E Ratio
- TURN N/A
- LPCN N/A
- Revenue Growth
- TURN 6.32
- LPCN 8630.55
- 52 Week Low
- TURN $3.16
- LPCN $2.31
- 52 Week High
- TURN $4.47
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- TURN 31.67
- LPCN 61.75
- Support Level
- TURN $3.21
- LPCN $4.89
- Resistance Level
- TURN $3.28
- LPCN $5.85
- Average True Range (ATR)
- TURN 0.05
- LPCN 0.38
- MACD
- TURN -0.01
- LPCN 0.04
- Stochastic Oscillator
- TURN 25.67
- LPCN 64.83
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.